Acrysof IQ PanOptix IOL
DeviceSingle-piece, ultraviolet and blue-light filtering, foldable, multifocal intraocular lens (IOL) inserted into the capsular bag during cataract surgery
Other names: Model TFNT00
NCT Number: NCT03706066
The purpose of this Post Marketing Study is to study the safety and effectiveness of the ACRYSOF IQ PanOptix intraocular lens (IOL) in an Indian population.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Alcon Investigative Site, Ahmedabad, Gujarat, India
The study population will consist of adult Indian males and females, at least 18 years of age or older at the time of screening, with no ocular pathology that could confound study outcomes, who are advised bilateral cataract extraction and who desire an IOL that provides the potential for correction of near, intermediate, and distance vision. Both eyes will be implanted. The second eye surgery will take place 15-30 days after the first eye surgery. Subjects will be followed for approximately 3 months after the second eye surgery. Total individual subject participation will be approximately 4 months. This study will be conducted in India.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Other protocol-specified inclusion and/or exclusion criteria may apply.
Single-piece, ultraviolet and blue-light filtering, foldable, multifocal intraocular lens (IOL) inserted into the capsular bag during cataract surgery
Other names: Model TFNT00
Per investigator's standard of care
Time frame: Month 3 (following second eye surgery)
Visual acuity will be assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) charts and reported in logarithm minimum angle of resolution (logMAR).
Alcon Research
Industry
An Observational, Prospective, Post-Marketing Clinical Study of the ACRYSOF® IQ PanOptix Multifocal IOL in an Indian Population
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06002399
Cataract, Eye Diseases
Brussels, Brussel Hoofdstedelijk Gewest, Belgium
View Trial DetailsNCT07086118
Cataract, Dexamethasone
Alexandria, Egypt
View Trial DetailsNCT06264830
Cataract, Eye Diseases
Taipei, Taiwan
View Trial DetailsNCT07767643
Anxiety, Anxiety Disorders
Yatağan, Muğla, Turkey (Türkiye)
View Trial Details